CANbridge NDA for Rare Disease Therapy Accepted in Taiwan
publication date: Mar 29, 2022
CANbridge Pharma’s NDA for maralixibat oral solution was accepted by Taiwan’s FDA as a therapy for cholestatic pruritus in patients with Alagille syndrome, an orphan disease. One year ago, the company acquired Greater China rights to the drug from Mirum Pharma of California in a $120 million deal. CANbridge has rights to commercialize the drug for three orphan indications: Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia. It filed an NDA for review in China previously, and Mirum is approved to launch the drug in the US. More details....
Stock Symbols: (HK: 1228) (NSDQ: MIRM)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.